Onxeo Announces Establishment of U.S. Subsidiary
Pharmaceutical and biotech industry veteran, Philippe Maitre, to head U.S subsidiary
Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced the creation of a U.S. subsidiary, based in New York City. The company also announced that experienced industry executive Philippe Maitre will head the U.S. subsidiary with the title of Executive VP & Chief of U.S. Operations. The U.S. subsidiary, to be named Onxeo US, will provide services to Onxeo as the company expands its development programs and establishes closer ties with the scientific and financial communities in the U.S.
Judith Greciet, CEO of Onxeo, commented: “The opening of a U.S. subsidiary, to be based in the key business, financial and medical hub of New York City, is a significant step and an important strategic initiative aimed at achieving our goal of connecting with more patients, physicians, Pharma and Biotech companies and investors in the United States. Having a dedicated and experienced team there will allow us to adapt our future activities to the needs of the largest healthcare market in the world. We are delighted to welcome Philippe Maitre to our team as the head of our U.S. subsidiary. Philippe is a seasoned biotech and pharmaceutical professional with experience leading several U.S. companies, with particular expertise in finance, business development and mergers and acquisitions. Philippe brings a wealth of valuable industry experience to Onxeo, andwill be responsible for establishing the US subsidiary and assisting with a series of strategic initiatives to serve Onxeo’s growth. We look forward to working closely with him to achieve our global objectives.”
Philippe Maitre commented: “It is a privilege to join Onxeo and to work with such a highly qualified team. Through compelling technologies and a strong product pipeline targeting orphan diseases, including the recent acquisition of DNA Therapeutics, there is significant potential to capitalize on numerous research and business opportunities in the U.S. I look forward to leading the U.S. operations and providing the input needed to advance the strategic development of the Company.”
Mr. Maitre brings more than 35 years of experience in the pharmaceutical and biotech industry, including nearly 15 years as Corporate Officer for US public companies. Mr. Maitre has served as Chief Executive Officer and Co-Founder of mAbRx, a biotech company developing monoclonal antibodies against cancer stem cells in partnership with the Duke Cancer Center. Prior to founding mAbRx, Philippe has been the Chief Executive Officer at Anosys, a cancer vaccine company spin-off from Aventis (today Sanofi). He has also served as a Chief Financial Officer for NASDAQ-listed companies Pharmaceutical Product Development Inc. (PPD Inc.) and Oscient Pharmaceuticals. Earlier in his career, Mr. Maitre served in various roles such as finance, business development and investor relations at companies Rhone Poulenc, Rhone Poulenc Rorer as well as Aventis, where he ultimately held the position of Senior Partner and Deputy CFO for Aventis Pharma Group.
Prior to joining the Pharma Industry, Mr. Maitre served in the French Ministry of Foreign Affairs where he was stationed in Libya. He earned his master’s in Finance from the Hautes Etudes de Commerce (HEC) Business School in Paris.
Source: Onxeo
